肺部疾病藥物市場：按適應症、藥物類別分類 - 全球預測 2023-2030 年

預計2023年全球肺病藥物市場將大幅成長579.8億美元，年複合成長率為3.20%，2030年將達到驚人的724.1億美元。

FPNV定位矩陣

FPNV 定位矩陣對於評估全球肺病治療市場至關重要。透過檢查業務策略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的特定需求做出明智的資訊。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對總收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發領域、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1.全球肺病治療藥物市場規模及預測為何？

2.在預測期內，COVID-19對全球肺病治療藥物市場的阻礙因素與影響為何？

3.在預測期內，全球肺病治療藥物市場需要投資哪些產品/細分市場/應用/領域？

4.貴公司在全球肺病藥物市場的競爭策略為何？

5. 全球肺病藥物市場的技術趨勢和法律規範是什麼？

6.全球肺病治療藥物市場主要廠商的市佔率為何？

7. 哪些型態和策略性措施被認為適合進入肺病藥物全球市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

• 市場動態
  • 促進因素
    • 吸菸、慢性呼吸道疾病發生率增加
    • 製藥創新和生物相似藥的可用性
    • 政府和非政府配合措施
  • 抑制因素
    • 藥品專利到期
  • 機會
    • 增加可支配收入並增加研發投資
    • 醫療費用增加
    • 透過合約製造進行藥物開發
  • 任務
    • 昂貴的新藥臨床試驗與商業化
• 市場趨勢
• COVID-19 的累積影響
• 俄羅斯-烏克蘭衝突的累積影響
• 高通膨的累積效應
• 波特五力分析
• 價值鍊和關鍵路徑分析
• 法律規範
• 客戶客製化

第6章 疾病治療藥物市場（依適應症）

• 過敏性鼻炎
• 氣喘
• 慢性阻塞性肺病
• 囊性纖維化
• 肺動脈高血壓

第7章 疾病治療藥物市場

• 抗膽鹼能藥物
• 抗白三烯
• 抗組織胺藥
• BETA2激動劑
• 組合藥物
• 單株抗體
• 口服和吸入性皮質類固醇

第8章 美洲肺部疾病治療市場

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美國

第9章 亞太肺部疾病治療市場

• 澳洲
• 中國
• 印度
• 印尼
• 日本
• 馬來西亞
• 菲律賓
• 新加坡
• 韓國
• 台灣
• 泰國
• 越南

第10章 歐洲、中東和非洲肺部疾病治療市場

• 丹麥
• 埃及
• 芬蘭
• 法國
• 德國
• 以色列
• 義大利
• 荷蘭
• 奈及利亞
• 挪威
• 波蘭
• 卡達
• 俄羅斯
• 沙烏地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公國
• 英國

第11章競爭形勢

• FPNV定位矩陣
• 市佔率分析：主要企業
• 競爭情境分析：主要企業

第12章上市公司名單

第13章附錄

• 討論指南
• 關於許可證和定價

The Global Pulmonary Drugs Market is forecasted to grow significantly, with a projected USD 57.98 billion in 2023 at a CAGR of 3.20% and expected to reach a staggering USD 72.41 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Pulmonary Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Pulmonary Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Indication, market is studied across Allergic Rhinitis, Asthma, Chronic Obstructive Pulmonary Disease, Cystic Fibrosis, and Pulmonary Arterial Hypertension. The Asthma is projected to witness significant market share during forecast period.

Based on Drug Class, market is studied across Anti-Cholinergic Agents, Anti-Leukotrienes, Antihistamines, Beta-2 Agonists, Combination Drugs, Monoclonal Antibodies, and Oral & Inhaled Corticosteroids. The Anti-Leukotrienes is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Pulmonary Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Pulmonary Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Pulmonary Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Pulmonary Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Pulmonary Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Pulmonary Drugs Market?

6. What is the market share of the leading vendors in the Global Pulmonary Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Pulmonary Drugs Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Pulmonary Drugs Market, by Indication, 2022 vs 2030
• 4.3. Pulmonary Drugs Market, by Drug Class, 2022 vs 2030
• 4.4. Pulmonary Drugs Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing incidence of chronic respiratory diseases, tobacco smoking
    • 5.1.1.2. Drug innovation and availability of biosimilars
    • 5.1.1.3. Government and non-government initiatives
  • 5.1.2. Restraints
    • 5.1.2.1. Patent expiry of drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing disposable income and rising investments in R&D
    • 5.1.3.2. Increasing healthcare spending
    • 5.1.3.3. Drug development through contract manufacturing
  • 5.1.4. Challenges
    • 5.1.4.1. Expensive clinical trials and commercialization of new drugs
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Pulmonary Drugs Market, by Indication

• 6.1. Introduction
• 6.2. Allergic Rhinitis
• 6.3. Asthma
• 6.4. Chronic Obstructive Pulmonary Disease
• 6.5. Cystic Fibrosis
• 6.6. Pulmonary Arterial Hypertension

7. Pulmonary Drugs Market, by Drug Class

• 7.1. Introduction
• 7.2. Anti-Cholinergic Agents
• 7.3. Anti-Leukotrienes
• 7.4. Antihistamines
• 7.5. Beta-2 Agonists
• 7.6. Combination Drugs
• 7.7. Monoclonal Antibodies
• 7.8. Oral & Inhaled Corticosteroids

8. Americas Pulmonary Drugs Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Pulmonary Drugs Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Pulmonary Drugs Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. FPNV Positioning Matrix
• 11.2. Market Share Analysis, By Key Player
• 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

• 13.1. Discussion Guide
• 13.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. PULMONARY DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. PULMONARY DRUGS MARKET SIZE, 2022 VS 2030
• FIGURE 3. PULMONARY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
• FIGURE 5. PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
• FIGURE 6. PULMONARY DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 7. PULMONARY DRUGS MARKET DYNAMICS
• FIGURE 8. PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 9. PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. PULMONARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 15. PULMONARY DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. PULMONARY DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. PULMONARY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 5. PULMONARY DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. PULMONARY DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. PULMONARY DRUGS MARKET SIZE, BY PULMONARY ARTERIAL HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 11. PULMONARY DRUGS MARKET SIZE, BY ANTI-CHOLINERGIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. PULMONARY DRUGS MARKET SIZE, BY ANTI-LEUKOTRIENES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. PULMONARY DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. PULMONARY DRUGS MARKET SIZE, BY BETA-2 AGONISTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. PULMONARY DRUGS MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. PULMONARY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. PULMONARY DRUGS MARKET SIZE, BY ORAL & INHALED CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 21. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 23. BRAZIL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 24. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 25. CANADA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 26. CANADA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 27. MEXICO PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 28. MEXICO PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 29. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 30. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 31. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 32. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 33. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 34. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 35. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 36. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 37. CHINA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 38. CHINA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 39. INDIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 40. INDIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 41. INDONESIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 42. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 43. JAPAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 44. JAPAN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 45. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 46. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 47. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 48. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 49. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 50. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 51. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 52. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 53. TAIWAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 55. THAILAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 56. THAILAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 57. VIETNAM PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 58. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 59. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 60. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 61. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 62. DENMARK PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. DENMARK PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 64. EGYPT PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 65. EGYPT PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 66. FINLAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 67. FINLAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 68. FRANCE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 69. FRANCE PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 70. GERMANY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 71. GERMANY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 72. ISRAEL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 73. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 74. ITALY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. ITALY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 76. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 77. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 78. NIGERIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 79. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 80. NORWAY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 81. NORWAY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 82. POLAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 83. POLAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 84. QATAR PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 85. QATAR PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 86. RUSSIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 87. RUSSIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 88. SAUDI ARABIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 89. SAUDI ARABIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH AFRICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 92. SPAIN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 93. SPAIN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 94. SWEDEN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 95. SWEDEN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 96. SWITZERLAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 97. SWITZERLAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 98. TURKEY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 99. TURKEY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 100. UNITED ARAB EMIRATES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 101. UNITED ARAB EMIRATES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 102. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 103. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 104. PULMONARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 105. PULMONARY DRUGS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 106. PULMONARY DRUGS MARKET LICENSE & PRICING